Moreover, Mutant KRAS tumor cell lines are more likely to amplify chromosome 12p, suggesting that enhancing the dose of oncogenic KRAS mutations is a beneficial trait (Fig. 6G, OR = 2.043, P = 0.0009). This evidence concerns the gene KRAS and neoplasm.